Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2473 - A phase 1 study evaluating the pharmacokinetics (PK) and safety of regorafenib (REG) in patients with advanced solid tumors with severe renal impairment (SRI)


08 Oct 2016


Poster Display


Daniel Renouf


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


D.J. Renouf1, H.W. Hirte2, C.L. O'Bryant3, Z.J. Trnkova4, A. Cleton4, F. Huang5, U. Mueller6, J. Ayoub7, A.C. Lockhart8, D.I. Quinn9, G.K. Dy10, M.B. Sawyer11

Author affiliations

  • 1 Division Of Medical Oncology, British Columbia Cancer Agency, V5Z 1M9 - Vancouver/CA
  • 2 Division Of Medical Oncology, Juravinski Cancer Centre and Escarpment Cancer Research Institute, Hamilton/CA
  • 3 Department Of Clinical Pharmacy, University of Colorado Cancer Center, Aurora/US
  • 4 Clinical Pharmacology Oncology, Bayer Pharma AG, Berlin/DE
  • 5 Clinical Pharmacology Oncology, Bayer HealthCare Pharmaceuticals, Whippany/US
  • 6 Clinical Statistics, ClinStat GmbH, Köln/DE
  • 7 Department Of Medicine, Centre Hospitalier de l'Université de Montréal, Montreal/CA
  • 8 Siteman Cancer Center, Washington University School of Medicine, St. Louis/US
  • 9 Norris Comprehensive Cancer Center, University of Southern California, Los Angeles/US
  • 10 Department Of Medicine, Roswell Park Cancer Institute, Buffalo/US
  • 11 Department Of Oncology, Cross Cancer Institute, Edmonton/CA


Abstract 2473


REG is an oral multikinase inhibitor used for the treatment of metastatic CRC and advanced GIST. This phase 1 study was designed to evaluate the PK and safety of REG in cancer patients with severe renal impairment (SRI; creatinine clearance [CLCR] ≥15 to


This was a phase 1, open-label, non-randomized, 2-parallel group study in patients with advanced solid tumors with severe vs normal/mild renal impairment (NCT01853046). REG 160 mg QD was administered as a single dose on Day 1 with a washout of ≥5 days, then as multiple doses in 28-day cycles (3 weeks on/1 week off). Antitumor activity was assessed according to RECIST v1.1 as a secondary endpoint. Blood samples were collected after single and multiple dose administration for PK analysis. Adverse events (AEs) were graded according to NCI CTCAE v4.0. Estimated CLCR was calculated using the Cockcroft–Gault equation.


24 patients (6 SRI and 18 CTR) were valid for PK and safety analyses and 21 patients for efficacy analysis. Baseline median (range) CLCR was 22.3 mL/min (22–31 mL/min) in the SRI and 82.6 mL/min (60–130 mL/min) in the CTR group. After single-dose REG, geometric mean AUC(0–tlast) was 76.6 mg × h/L in the SRI and 67.2 mg × h/L in the CTR group, whereas mean terminal half-lives were 27.9 h and 28.7 h, respectively. Inter-subject variability of AUC(0–tlast) was moderate in the 2 groups (CV 50.3% SRI and 45.5% CTR). After repeated dosing, the geometric mean AUC(0–24) for REG was 55.9 mg·h/L in the SRI and 57.5 mg·h/L in the CTR group. The most common REG-related treatment-emergent AEs were hand–foot skin reaction (54%), diarrhea (46%), fatigue (46%), nausea (42%), decreased appetite (42%), and hypertension (42%). The best response observed was stable disease in 15/21 (71%) patients.


The PK of REG 160 mg QD was not affected by severe renal impairment. No safety signal was detected for a potential influence of severe renal impairment on the safety profile of REG. No dose modification is recommended for renal impairment.

Clinical trial identification


Legal entity responsible for the study





D.J. Renouf: Research funding: Bayer. H.W. Hirte: Advisory board: AstraZeneca, Roche. C.L. O'Bryant: Advisory board: Amgen, Heron Therapeutics. Corporate-sponsored research: Bayer, Pfizer, AstraZeneca. Speakers bureau: Amgen. Z.J. Trnkova, F. Huang: Other substantive relationships: Bayer (employee). A. Cleton: Stock ownership: Bayer, AstraZeneca, Pfizer. Other substantive relationships: Bayer (employee). U. Mueller: Advisory board: Bayer. Other substantive relationships: ClinStat GmbH (employee). D.I. Quinn: Advisory boards: Bayer All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings